2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Tuesday, October 23, 2018

9:00AM-11:00AM: Abstract Number: 2678

Integrated Safety Profile of Atacicept from All Clinical Studies to Date

Systemic Lupus Erythematosus – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2224

Interactions between Serum Urate-Associated Genetic Variants and Sex on Gout Risk in a European Population

Metabolic and Crystal Arthropathies – Basic and Clinical Science Poster II

9:00AM-11:00AM: Abstract Number: 2130

Interferon Induced Gene Transcripts Are Differentially Upregulated in the Kidney of Lupus Nephritis Patients Irrespective of Activity or Damage

Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 2114

Interferon Kappa Regulates Apoptotic Response to UVB in Control and Lupus Keratinocytes

Systemic Lupus Erythematosus – Etiology and Pathogenesis Poster III

9:00AM-11:00AM: Abstract Number: 2685

Interferon-Inducible Gene Expression Kit As a Potential Diagnostic Test for Anifrolumab: Analytical Validation for Use in Clinical Trials

Systemic Lupus Erythematosus – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2287

Interim Results of an Open-Label Study Assessing Efficacy and Safety of Adrenocorticotropic Hormone Gel for Treatment of Refractory Cutaneous Manifestations of Dermatomyositis

Muscle Biology, Myositis and Myopathies Poster III: Treatment and Classification Criteria

9:00AM-11:00AM: Abstract Number: 2000

Interleukin-1β, Oxidative Stress and Basic Calcium Phosphate Crystals Induce Osteoarthritis-like Changes in Chondrocyte Phenotype By Altering the Expression of PERIOD2, a Core Component of the Chondrocyte Circadian Clock

Osteoarthritis and Joint Biology – Basic Science Poster II

9:00AM-11:00AM: Abstract Number: 2776

Interleukin-6 Expression in Inflamed and Non-Inflamed Temporal Arteries from Patients with Giant Cell Arteritis

Vasculitis Poster III: Immunosuppressive Therapy in Giant Cell Arteritis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 2322

Intervals of Bone Mineral Density Measurement during Treatment for Osteoporosis in Patients with Rheumatoid Arthritis

Osteoporosis and Metabolic Bone Disease – Basic and Clinical Science Poster

9:00AM-11:00AM: Abstract Number: 2636

Investigating Lupus Nephritis Patient Outcomes Receiving Belatacept Post Renal Transplant Using the UNOS Database

Systemic Lupus Erythematosus – Clinical Poster III: Treatment

9:00AM-11:00AM: Abstract Number: 2019

Investigating Urine S100A4 and Podocyte Proteins As Biomarkers of Lupus Nephritis Activity

Pediatric Rheumatology – Basic Science Poster

9:00AM-11:00AM: Abstract Number: 2713

Is Effectiveness of Immunosuppression for Interstitial Lung Disease in Systemic Sclerosis (SSc) Modified By Lung Disease Severity or SSc Duration?

Systemic Sclerosis and Related Disorders – Clinical Poster III

9:00AM-11:00AM: Abstract Number: 2782

Is It Necessary to Hold Anticoagulation Prior to Temporal Artery Biopsy?

Vasculitis Poster III: Immunosuppressive Therapy in Giant Cell Arteritis and Polymyalgia Rheumatica

9:00AM-11:00AM: Abstract Number: 2393

Is Methotrexate-Induced Nausea in Juvenile Idiopathic Arthritis Influenced By Anxiety or Coping Strategies?

Pediatric Rheumatology – Clinical Poster III: Juvenile Idiopathic Arthritis and Uveitis

9:00AM-11:00AM: Abstract Number: 2555

Ixekizumab Treatment Results in Rapid and Sustained Improvements in the Disease Activity Index for Psoriatic Arthritis (DAPSA) in Patients Naïve to Biologic Dmards or with Previous Inadequate Response to TNF Inhibitors

Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster III: Treatment

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].